KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest & Investment Income (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Interest & Investment Income for 6 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 12.29% year-over-year to $3.5 million, compared with a TTM value of $13.6 million through Dec 2025, down 20.02%, and an annual FY2025 reading of $13.6 million, down 20.02% over the prior year.
  • Interest & Investment Income was $3.5 million for Q4 2025 at Aurinia Pharmaceuticals, up from $3.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.6 million in Q4 2023 and bottomed at -$852000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $2.6 million, with a median of $3.4 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income tumbled 80.67% in 2021, then surged 1355.73% in 2023.
  • Year by year, Interest & Investment Income stood at -$852000.0 in 2021, then surged by 441.43% to $2.9 million in 2022, then skyrocketed by 57.03% to $4.6 million in 2023, then decreased by 12.7% to $4.0 million in 2024, then decreased by 12.29% to $3.5 million in 2025.
  • Business Quant data shows Interest & Investment Income for AUPH at $3.5 million in Q4 2025, $3.3 million in Q3 2025, and $3.2 million in Q2 2025.